Spinal Fusion Market Report: Forecast and Trends Analysis to 2036
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: Globenewswire
- Market Size Analysis: The spinal fusion market is projected to continue growing through 2036, with detailed intervention volumes and market value data across 39 countries aiding companies in strategic decision-making.
- Surgical Indications: Spinal fusion surgeries are primarily used to treat a variety of spine-related conditions such as degenerative disc disease, spondylolisthesis, and spinal stenosis, indicating the broad application potential of this market.
- Competitive Landscape: The report analyzes market shares and competitive dynamics of key players like Medtronic, DePuy Synthes, and Stryker, providing investors with deep market insights.
- Data Sources and Methodology: By integrating real-world data from government procedure databases and hospital purchasing databases, the report ensures accuracy and reliability of market trends, supporting companies' procurement and investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 243.190
Low
190.00
Averages
218.50
High
240.00
Current: 243.190
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
Investors Shift Focus to Dividend-Paying Stocks Amid Market Volatility
- Market Volatility Impact: The S&P 500 has lost about 2% in 2026 due to rising oil prices from the Iran war, prompting investors to seek high-dividend stocks perceived as risk-averse to navigate the turbulent market.
- Dividend Aristocrats Outperformance: Both the ProShares S&P 500 Dividend Aristocrats ETF and the Vanguard High Dividend Yield ETF have gained approximately 4% year-to-date, indicating strong performance of income-paying stocks, particularly during a rate-cutting cycle.
- Colgate-Palmolive Dividend Increase: Colgate-Palmolive's stock has risen about 14%, and it raised its quarterly dividend from 52 cents to 53 cents per share, demonstrating resilience in a challenging operating environment and confidence in long-term shareholder value creation.
- Johnson & Johnson Drug Development: Johnson & Johnson's stock has increased by about 17% year-to-date, and it recently announced significant results from its Phase 1 trial for bladder cancer treatment, further solidifying its leadership position in the pharmaceutical industry.
See More
Tax Bill Boosts Refunds Amid Market Volatility
- Increased Refunds: The tax bill passed last year has reduced individual taxes by $129 billion for 2025, resulting in many taxpayers receiving larger refunds this tax season, with the average refund amount rising from $3,450 to over $3,800, thereby enhancing disposable income for consumers.
- Investment Recommendations: Given the heightened market volatility, taxpayers are advised to invest their refunds rather than spend them, particularly as the ongoing conflict in the Middle East has led to stock market declines, making retirement portfolio investments crucial for long-term financial health.
- Defensive Investments: Sectors such as consumer staples, healthcare, and utilities are expected to perform well during economic slowdowns, with companies like Costco, Johnson & Johnson, and NextEra Energy maintaining stable demand, making them attractive options for investors seeking safety.
- Market Performance Analysis: Despite increased overall market volatility, certain defensive stocks have outperformed the broader market over the past month, indicating that selecting appropriate investment targets can effectively mitigate risks and yield returns in uncertain economic conditions.
See More
Analysis of Investment Opportunities in Defensive Sectors
- Tax Refund Impact: The tax bill passed last year reduced individual taxes by $129 billion for 2025, resulting in an increase in the average tax refund from $3,450 to $3,800 this year, which is expected to stimulate consumer spending and drive economic recovery.
- Defensive Sector Performance: Amid heightened market volatility, stocks in defensive sectors such as consumer staples, healthcare, and utilities have outperformed the broader market, particularly discount retailers like Costco, Target, and Walmart, which continue to attract consumers during economic downturns.
- Healthcare Investment Potential: Companies like Johnson & Johnson and CVS provide essential medical supplies and services, maintaining strong demand even in adverse economic conditions, highlighting their investment value in uncertain markets.
- Utility Stability: Utility companies such as American Water Works, Brookfield Infrastructure, and NextEra Energy offer essential services that remain in demand regardless of economic fluctuations, making them a safe choice for investors seeking stability.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for Cancer Treatment
- Supply Agreement Established: Monte Rosa Therapeutics (GLUE) has signed a supply agreement with Johnson & Johnson (JNJ) to evaluate MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) patients, marking a strategic collaboration in cancer treatment.
- Clinical Trial Plans: Under the agreement, Monte Rosa will conduct and sponsor the trial, planning to initiate a signal-confirming phase 2 study targeting AR mutant patients in Q3 2026, with an expected enrollment of up to 25 patients to efficiently assess the efficacy and safety of MRT-2359 plus ERLEADA.
- Positive Market Reaction: Following the announcement, Monte Rosa's shares rose by 1.6% to $16.28, reflecting market optimism regarding the new research direction and potentially boosting investor confidence.
- Research Evaluation Metrics: The study will evaluate key metrics including PSA response, RECIST response, duration of response, progression-free survival (PFS), and safety, with the potential to expand to other patient subsets if activity in the AR mutant population is confirmed.
See More
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
Investors Shift Focus to Dividend-Paying Stocks Amid Market Volatility
- Market Volatility Impact: The S&P 500 has lost about 2% in 2026 due to rising oil prices from the Iran war, prompting investors to seek high-dividend stocks perceived as risk-averse to navigate the turbulent market.
- Dividend Aristocrats Outperformance: Both the ProShares S&P 500 Dividend Aristocrats ETF and the Vanguard High Dividend Yield ETF have gained approximately 4% year-to-date, indicating strong performance of income-paying stocks, particularly during a rate-cutting cycle.
- Colgate-Palmolive Dividend Increase: Colgate-Palmolive's stock has risen about 14%, and it raised its quarterly dividend from 52 cents to 53 cents per share, demonstrating resilience in a challenging operating environment and confidence in long-term shareholder value creation.
- Johnson & Johnson Drug Development: Johnson & Johnson's stock has increased by about 17% year-to-date, and it recently announced significant results from its Phase 1 trial for bladder cancer treatment, further solidifying its leadership position in the pharmaceutical industry.
See More
Tax Bill Boosts Refunds Amid Market Volatility
- Increased Refunds: The tax bill passed last year has reduced individual taxes by $129 billion for 2025, resulting in many taxpayers receiving larger refunds this tax season, with the average refund amount rising from $3,450 to over $3,800, thereby enhancing disposable income for consumers.
- Investment Recommendations: Given the heightened market volatility, taxpayers are advised to invest their refunds rather than spend them, particularly as the ongoing conflict in the Middle East has led to stock market declines, making retirement portfolio investments crucial for long-term financial health.
- Defensive Investments: Sectors such as consumer staples, healthcare, and utilities are expected to perform well during economic slowdowns, with companies like Costco, Johnson & Johnson, and NextEra Energy maintaining stable demand, making them attractive options for investors seeking safety.
- Market Performance Analysis: Despite increased overall market volatility, certain defensive stocks have outperformed the broader market over the past month, indicating that selecting appropriate investment targets can effectively mitigate risks and yield returns in uncertain economic conditions.
See More
Analysis of Investment Opportunities in Defensive Sectors
- Tax Refund Impact: The tax bill passed last year reduced individual taxes by $129 billion for 2025, resulting in an increase in the average tax refund from $3,450 to $3,800 this year, which is expected to stimulate consumer spending and drive economic recovery.
- Defensive Sector Performance: Amid heightened market volatility, stocks in defensive sectors such as consumer staples, healthcare, and utilities have outperformed the broader market, particularly discount retailers like Costco, Target, and Walmart, which continue to attract consumers during economic downturns.
- Healthcare Investment Potential: Companies like Johnson & Johnson and CVS provide essential medical supplies and services, maintaining strong demand even in adverse economic conditions, highlighting their investment value in uncertain markets.
- Utility Stability: Utility companies such as American Water Works, Brookfield Infrastructure, and NextEra Energy offer essential services that remain in demand regardless of economic fluctuations, making them a safe choice for investors seeking stability.
See More
Monte Rosa Enters Supply Agreement with Johnson & Johnson for Cancer Treatment
- Supply Agreement Established: Monte Rosa Therapeutics (GLUE) has signed a supply agreement with Johnson & Johnson (JNJ) to evaluate MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) patients, marking a strategic collaboration in cancer treatment.
- Clinical Trial Plans: Under the agreement, Monte Rosa will conduct and sponsor the trial, planning to initiate a signal-confirming phase 2 study targeting AR mutant patients in Q3 2026, with an expected enrollment of up to 25 patients to efficiently assess the efficacy and safety of MRT-2359 plus ERLEADA.
- Positive Market Reaction: Following the announcement, Monte Rosa's shares rose by 1.6% to $16.28, reflecting market optimism regarding the new research direction and potentially boosting investor confidence.
- Research Evaluation Metrics: The study will evaluate key metrics including PSA response, RECIST response, duration of response, progression-free survival (PFS), and safety, with the potential to expand to other patient subsets if activity in the AR mutant population is confirmed.
See More
